Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OMHE_Developed_Marijuana_based_Pain_Treatment_Starting_FDA_Approval_Process
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Takes_MJ_Medicine_to_FDA__for_Approval*Also_Supplying_CBD_Ointments_to_Doctors
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Projected_Annual_Rev_to_Increase_by_7Million_to_a_Total_of_$11.3Million
OMHE also developed Marijuana Medicine and applying for FDA Approval
Current Annual Revenue....................=$4.3 Million
Projected Annual Addition..................=$7.0 Million
Total Projected Annual Revenue....=$11.3 Million
12/05/2017 MMJ Medicine Development & FDA Approval and Revenue Add News - Read Here
OMHE_is_The_Champion_of_6_Pharma_Industries_Applying _for_FDA_Approval_for_MMJ _Medicine
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS Ready to Rise to $1
OMHE_Marijuana_based_Pain_Medicine_Starting_FDA_Registration_QB_Uplist
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Projected_Annual_Rev_to_Increase_by_7Million_to_a_Total_of_$11.3Million
Current Annual Revenue....................=$4.3 Million
Projected Annual Addition..................=$7.0 Million
Total Projected Annual Revenue....=$11.3Million
12/05/2017 MMJ Medicine Development & FDA Approval and Revenue Add News - Read Here
OMHE_Takes_MJ_Medicine_to_FDA__for_Approval*Also_Supplying_CBD_Ointments_to_Doctors
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Buy OMHE on dip. MMJ Drug. FDA Approval.
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Last_day_for_Bargain_Hunters_OMHE_developed_MMJ_Medicine_Next_FDA_Approval
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
Buy_on_dip_OMHE_developed_MMJ_Medicine_Applying_for_FDA_Approval
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Approval_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Registration_OTCQB_Uplist_on_the_WAY!!!
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Heading to $1 PPS
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Anyone_New_Joining_Us_On_OMHE_Board_OMHE_is_Going_to_FDA_for_MMJ_drug_Approval
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_is_The_Champion_of_6_Pharma_Industries_Applying _for_FDA_Approval_for_MMJ_Medicine
Check Their Website
1) Specialty Pharmacy
2) Regenerative Medicine
3) Anti-Aging
4) Skincare Technologies
5) Cannabis Technologies – Another PR is Expected in Few Days!!!
6) Global Wellness
OMHE has scientists, R&D Lab, plan and is ready to market/sell Marijuana based Pain treatment therapeutics and medicine. Also, OTCQB upgrade is on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS Ready to Rise to $1
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Registration_OTCQB_Uplist_on_the_WAY!!!
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine_Therapeutics
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE _Marijuana_based_Pain_Medicine_Starting_FDA_Registration_QB_Uplist
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Medicine_Starting_FDA_Registration_Process
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_is_Heading_to_FDA_for_the_Approval_of_its_MMJ_based_Pain_Medicine
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE*Licensed_Medical_Marijuana_Cultivation*Shares_Restructuring*QB_Uplist_are_NEXT
12/05/2017 OMHE Cannabinoid-based Therapeutics / Medicine Development & FDA Approval Plan News - Read Here
OMHE is doing all in a planned manner:
1) Purchased VTCQ shell, for a $4.6Mil existing rev company
2) Changed to OMHE
3) Completed 17Q1, Q2 10-Qs
4) Announced CEO Name
5) Reviewed/Released 17Q1, Q2 10-Qs
6) Announced OTCQB uplist plan
7) In Feb 2017, CEO released his comprehensive vision
8) Released 17Q3 10-Q timely (within allowed extended period)
9) R&D work and uplist was in progress in the background
10) Secured $1Mil financing
11) Developed/Announced Cannabis/Biotech R&D Lab launch and lab leader's announcement
Expected upcoming BIG developments/announcements include:
12) Progress on OTCQB uplist << To Be Announced
13) Revenue Augment plan<< Partially Announced
14) FY2017 Report Release << Completed
15) Cannabinoid therapy development for pain management << In Progress
16) New Business acquisitions << To Be Announced
17) Cannabis product/medicine development in OMHE R&D Lab<< Completed-Fast Track FDA Approval In-Progress
18) News about Anti-aging product developed by its own scientist << Announced
19) Marketing/Sales/Rev generation from their own developed products << In Progress
20) Huge investments because R&D work attract big investors << To Be Announced
21) Shares restructuring << Announced – Will be filed Soon
22) Collaboration/joint venture with one of the largest European cannabis companies << In Progress
23) Licensed Medical marijuana cultivation << In Progress
OMHE PPS Ready to Rise to $1
OMHE_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine_Therapeutics
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
Welcome_Zenrush_Time_To_Gobble_Gobble_OMHE_PPS_on_the_RiSE_Because.....
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists with FDA/regulatory approval experience joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
OMHE PPS Ready to Rise to $1
OMHE_Developed_Cannabinoid_Based_TherapeuticsMedicine_Onto_FDA_Registration
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_PPS_Rising_Applying_for_MMJ_Drug_FDA_Registration_OTCQB_Uplist_on_the_WAY!!!
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Developed_Marijuana_based_Pain_Treatment_Starting_FDA_Approval_Process
(1) In Feb 2017 OMHE shared its vision and indicated its plan on working on therapeutic cannabis products and licensed medical marijuana cultivation.
CLICK HERE TO READ FEB 2017 OMHE VISION & FUTURE PLANS
(2) In My 2017 OMHE announced the opening of its Biotech R&D Lab.
CLICK HERE TO READ MAY 2017 LAB ANNOUNCEMENT
(3) In June 2017 Biotech scientists joined OMHE.
CLICK HERE TO READ JUNE 2017 SCIENTISTS ANNOUNCEMENT
(4) In Nov 2017 OMHE updated about cannabinoid-based drug-development.
CLICK HERE TO READ NOV 2017 DRUG DEVELOPMENT UPDTE
(5) Now in Dec 2017 OMHE announced its plan already in motion to create a drug candidate compelling to Big Pharma, development of cannabidiol pain treatment therapeutic & medicine and filing of FDA registration by employing an FDA regulations-savvy, ‘fast-track’ pipeline strategy.
CLICK HERE TO READ DEC 2017 FDA REGISTRATION UPDATE
From 12/05/2017 MMJ Medicine Development & FDA Approval Plan News
OMHE_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Applying_for_FDA_Registration_for_MJ_Based_Pain_Treatment_Medicine_Therapeutics
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Huge_News_MMJ_FDA_Approval!!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE _Marijuana_based_Pain_Medicine_Starting_FDA_Registration_QB_Uplist
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Pain_Treatment_Starting_FDA_Approval
Also, OTCQB Uplist on the way!
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE_Developed_Marijuana_based_Pain_Therapeutic_Medicine_FDA_Approval_is_Starting
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
For_Anyone_New_Joining_Us_On_OMHE_Board**YES!!OMHE_is_Going_to_FDA
12/05/2017 MMJ Medicine Development & FDA Approval Plan News - Read Here
OMHE PPS is Rising...Enter NOW!
OMHE_CEO_PR’d_just_3_Weeks_ago_Working_on_Big_Marijuana_Pharma_Projects As stated in 11/14/2017 Letter. Will_Release_NEXT_PR_SOON
Link To The Latest, 11/14/2017 OMHE CEO Letter
Omni Health, Inc. Releases Letter to Shareholders
•November 14, 2017
Comment
MIAMI, FL--(Marketwired - Nov 14, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health's annual revenues have grown to more than $4.6 million; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I'm working diligently to create a cycle of perpetual growth that over time will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., ( OTC PINK : OMHE ) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
OMHE_PPS_will_Continue_to_Rise_As_OMHE_Marijuana_Medicine_R&D_plan_is_SOLID
Link To The Latest, 11/14/2017 OMHE CEO Letter
Omni Health, Inc. Releases Letter to Shareholders
•November 14, 2017
Comment
MIAMI, FL--(Marketwired - Nov 14, 2017) - Omni Health, Inc., ( OTC PINK : OMHE ), a vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering, today published a letter to its Shareholders. The Letter to Shareholders provides a mid-year corporate update, including recent accomplishments in cannabinoid biotechnology and upcoming milestones, and is as follows:
Dear Shareholders,
As we move into the second quarter (our financial year ends April 30th), I can honestly say that I have never been more optimistic about our opportunities for success. Omni Health's annual revenues have grown to more than $4.6 million; it is with a great sense of gratitude and pride in our company that I share my confidence that this success will continue into the future, as we continue to grow and strengthen. I would also like to express my sincere appreciation for your patience with the process of assiduously refining and growing our company, our brand, and our network of expert collaborators. These factors are driving novel and existing prospects that will position our Company as an emergent, dominant presence in key, lucrative markets.
Omni Health is an exceptional company with an extraordinary heritage and a promising future. The current stock price does not accurately reflect our present growth in vision or value; however, steadfast adherence to our core values and vision is bearing fruits of progress that will hopefully soon become evident in our stock price. To keep our Shareholders abreast of such growth, Omni Health will be updating current shareholders, and potential new shareholders, with updates via press releases starting this week.
I am also an Omni Health Shareholder and have personally invested a significant amount of my own capital into the Company. Please rest assured that I'm working diligently to create a cycle of perpetual growth that over time will surely result in sustainable gain for all our shareholders. The realization of strategic growth planning targeting vital, commerce-friendly environments will result in a strong and sustainable business upturn.
I am delighted to report that we reached the end of a long process that began over ten months ago, culminating in the several high-profile developments we will soon be announcing. There have been extensive negotiations that we have not talked about publicly, but as we are now in the final stages of these negotiations, we can now speak more openly about two important developments that will bring the Company to a completely new level of success.
The first, which we can share now, is development in the sphere of a cannabinoid-based drug-development. In collaboration with Dr. Karyemaitre Aliffe, MD, Omni Health is finalizing a regulatory path to commercialization of a breakthrough, proprietary compound agent with the potential to treat chronic pain.
Dr. Aliffe is a forward-looking, Harvard University and Stanford University-trained, entrepreneurial physician-scientist executive with over 25 years of experience building corporate growth and profitability with strategic visionary leadership. His core competencies include practicable innovation enabling competitive expansion into lucrative niche markets while effectively harmonizing internal medical and therapeutic standards with regional and national regulatory guidelines. From the laboratory to the operating room, his specialty has always been translational biotherapeutics -- evidence-based, biopharmaceutical, phytomedicinal and medicinal nutraceutical development capturing health professional and consumer self-care markets across North America, Europe, Australia and Asia. An eloquent and effective multilingual communicator, Dr. Aliffe is also fluent in science and marketing, medicine and wellness, medicinal botany and clinical pharmacology, internet media and professional-to-consumer networking.
The global market for pain management will grow from nearly $36.1 Billion in 2017 to $52.0 Billion by 2022. Recent stringent regulations regarding the usage of opioids and a number of opioid pain drugs being pulled from the market create an additional opportunity to fill the void left by the withdrawal of these drugs. As such, there is a significant potential for cannabinoid biotherapeutics to truly seize the day in the treatment of chronic pain and other debilitating conditions.
We are currently in negotiations with several private investor groups to raise sufficient capital for this initiative.
We will continue to provide updates over the coming weeks that will include a collaboration/joint venture with one of the largest European cannabis companies pertaining to the import and distribution of breakthrough cannabidiol-centered consumer products that we are presently developing for them. The first steps in the commercialization process will involve the establishment of a strong presence in the European market, the benefits of which will be elaborated upon in future communications.
Again, I thank you for your patience and graciously anticipate your enthusiasm.
Sincerely,
Andrey Soloviev
CEO
Omni Health, Inc.
About Omni Health, Inc.
Omni Health, Inc., ( OTC PINK : OMHE ) is a 40 year old vertically integrated healthcare company dedicated to the development of pharmaceutical, anti-aging products, and cannabis biotech engineering with a robust pipeline of new products and breakthrough innovation.
OMHE_Will_Reveal_MJ_Medicine_Distro_Plan__HUGE_PR_is_in_MAKING_PPS_Will_FLY_TO_SKY
OMHE CEO had conveyed OMHE business plan in Feb 2017. Since then OMHE acquired new business, inducted scientists, established advanced Biotech R&D lab, conducting research to develop cannabinoid-based drug therapies. Latest update was provided on 11/14/2017: cannabinoid-based pain treatment medicine is ready to be marketed; talks are underway with large European companies. Target markets include North America, Europe, Australia and Asia.
I am satisfied with OMHE's progress!!
BIG_Announcement_OMHE_is_Diving_into_$36Billion_Pain_Management_GlobalMarket
OMHE is fulfilling one promise after another; recent rise in PPS shows investors confidence. OMHE's next PR is NEAR!!!!!!!!!!!
Link To News